[ad_1]
Adastra Holdings Ltd. XTRX (FRA: D2EP) XTXXF reported on Wednesday that Adastra Labs got the green light from Health Canada earlier this month for its amendment to include cocaine as a substance that the company can legally possess, produce, sell and distribute.
The Langley, British Columbia-based company obtained its Controlled Drug and Substances Dealer’s License on August 24, 2022. The dealer’s Llicense also allows Adastra to possess, produce, sell and distribute up to 1,000 grams of psilocybin and psilocin.
In addition, the amended license enables Adastra to interact with up to 250 grams of cocaine and to import coca leaves to manufacture and synthesize the substance.
“Harm reduction is a critically important and mainstream topic, and we are staying at the forefront of drug regulations across the board,” Michael Forbes, CEO of Adastra, said. “We proactively pursued the amendment to our Dealer’s License to include cocaine back in December 2022. We will evaluate how the commercialization of this substance fits in with our business model at Adastra in an effort to position ourselves to support the demand for a safe supply of cocaine.”
The company also noted that in British Columbia, there is a three-year exemption under the Controlled Drugs and Substances Act (CDSA) for adults over 18 to possess up to 2.5 grams of opioids, cocaine, methamphetamine, MDMA or some combination thereof between January 31, 2023, and January 31, 2026.
Benzinga Cannabis Capital Conference
The most successful cannabis business event in the world, the Benzinga Cannabis Capital Conference, returns to Miami for its 16th edition.
This is the place where DEALS GET DONE, where money is raised, M&A starts, and companies meet investors and key partners. Join us at the Fontainebleau Miami Beach Hotel in Florida on April 11-12. Don’t miss out.
Secure your tickets now. Prices will go up soon.
Photo: Courtesy of Scott Graham on Unsplash
[ad_2]
Image and article originally from www.benzinga.com. Read the original article here.